BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Morilla AM, Álvarez-Argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol 2019;42:476-85. [PMID: 31324461 DOI: 10.1016/j.gastrohep.2019.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
3 McNicholl AG, Gisbert JP. Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified? Gastroenterol Hepatol 2019;42:461-3. [PMID: 31113653 DOI: 10.1016/j.gastrohep.2019.03.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
5 Mcnicholl AG, Amador J, Ricote M, Cañones‐garzón PJ, Gene E, Calvet X, Gisbert JP; the Spanish Primary Care Societies SEMFyC, SEMERGEN and SEMG, the Spanish Association of Gastroenterology, the OPTICARE Long‐Term Educational Project. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions. Helicobacter 2019. [DOI: 10.1111/hel.12593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
8 Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. Helicobacter 2020;25:e12693. [PMID: 32285569 DOI: 10.1111/hel.12693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
10 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
11 Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29:552-559. [PMID: 28350745 DOI: 10.1097/meg.0000000000000822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Botija G, García Rodríguez C, Recio Linares A, Campelo Gutiérrez C, Pérez-Fernández E, Barrio Merino A. [Antibiotic resistances and eradication rates in Helicobacter pylori infection]. An Pediatr (Engl Ed) 2020:S1695-4033(20)30448-3. [PMID: 33334694 DOI: 10.1016/j.anpedi.2020.10.006] [Reference Citation Analysis]
13 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Salillas S, Galano-Frutos JJ, Mahía A, Maity R, Conde-Giménez M, Anoz-Carbonell E, Berlamont H, Velazquez-Campoy A, Touati E, Mamat U, Schaible UE, Gálvez JA, Díaz-de-Villegas MD, Haesebrouck F, Aínsa JA, Sancho J. Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies. Int J Mol Sci 2021;22:10137. [PMID: 34576300 DOI: 10.3390/ijms221810137] [Reference Citation Analysis]
16 Fernández-Reyes M, Tamayo E, Rojas-Rengifo D, Fischer W, Carrasco-García E, Alonso M, Lizasoain J, Bujanda L, Cosme Á, Montes M. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. Eur J Clin Invest 2019;49:e13150. [PMID: 31192451 DOI: 10.1111/eci.13150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373 [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
18 de Lázaro Torres ML, Borderías Uribeondo P, Morales Yago FJ. Citizen and Educational Initiatives to Support Sustainable Development Goal 6: Clean Water and Sanitation for All. Sustainability 2020;12:2073. [DOI: 10.3390/su12052073] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Mcnicholl AG, Ducons J, Barrio J, Bujanda L, Forné-bardera M, Aparcero R, Ponce J, Rivera R, Dedeu-cuso JM, Garcia-iglesias P, Montoro M, Bejerano A, Ber-nieto Y, Madrigal B, Zapata E, Loras-alastruey C, Castro M, Nevarez A, Mendez I, Bory-ros F, Miquel-planas M, Vera I, Nyssen OP, Gisbert JP. Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. Gastroenterología y Hepatología 2017;40:651-7. [DOI: 10.1016/j.gastrohep.2017.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
21 Brennan D, O’morain C, Mcnamara D, Smith SM. Molecular Detection of Antibiotic-Resistant Helicobacter pylori. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 29-36. [DOI: 10.1007/978-1-0716-1302-3_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Montes M, Pérez-trallero E. How long until routine Helicobacter pylori antimicrobial susceptibility testing? The Lancet Infectious Diseases 2017;17:130-1. [DOI: 10.1016/s1473-3099(17)30005-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
23 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens 2020;10:15. [PMID: 33379336 DOI: 10.3390/pathogens10010015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Valencia ME, Montejano R, Moreno V, Martín Carbonero L, Bernardino JI, Serrano L. [Helicobacter pylori infection in the HIV + population: a comorbidity to think about]. Rev Esp Quimioter 2020;33:68-72. [PMID: 31933346 DOI: 10.37201/req/033.2019] [Reference Citation Analysis]
26 Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol 2018; 24(22): 2373-2380 [PMID: 29904244 DOI: 10.3748/wjg.v24.i22.2373] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
27 Cubiella J, Pérez Aisa Á, Cuatrecasas M, Díez Redondo P, Fernández Esparrach G, Marín-Gabriel JC, Moreira L, Núñez H, Pardo López ML, Rodríguez de Santiago E, Rosón P, Sanz Anquela JM, Calvet X; en representación de la Asociación Española de Gastroenterología, la Sociedad Española de Endoscopia Digestiva y la Sociedad Española de Anatomía Patológica. Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. Gastroenterol Hepatol 2021;44:67-86. [PMID: 33252332 DOI: 10.1016/j.gastrohep.2020.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Macías-garcía F, Llovo-taboada J, Díaz-lópez M, Bastón-rey I, Domínguez-muñoz JE. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017;22:e12440. [DOI: 10.1111/hel.12440] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
30 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
31 Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [DOI: 10.1111/hel.12586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98:e15180. [PMID: 30985706 DOI: 10.1097/md.0000000000015180] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
34 Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-915. [PMID: 31424296 DOI: 10.1080/17512433.2019.1654858] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
35 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Liatsos C, Georgopoulos SD. Helicobacter pylori best treatment approach: should a national consensus be the best consensus? Ann Gastroenterol 2017;30:704-6. [PMID: 29118570 DOI: 10.20524/aog.2017.0183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
37 Brennan DE, O'Morain C, McNamara D, Smith SM. Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success. World J Gastrointest Pathophysiol 2022; 13(1): 34-40 [DOI: 10.4291/wjgp.v13.i1.34] [Reference Citation Analysis]
38 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
40 Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, Huguet JM, Pérez-Lasala J, Molina-Infante J, Barrio J, Fernández-Salazar L, Lanas Á, Perona M, Domínguez-Cajal M, Ortuño J, Gómez-Rodríguez BJ, Almela P, Botargués JM, Núñez Ó, Modolell I, Gómez J, Ruiz-Zorrilla R, De la Coba C, Huerta A, Iyo E, Pozzati L, Antón R, Barenys M, Angueira T, Fernández-Bermejo M, Campillo A, Alcedo J, Pajares-Villaroya R, Mego M, Bermejo F, Dominguez-Jiménez JL, Titó L, Fernández N, Pabón-Carrasco M, Cosme Á, Mata-Romero P, Alcaide N, Ariño I, Di Maira T, Garre A, Puig I, Nyssen OP, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics (Basel) 2020;10:13. [PMID: 33375717 DOI: 10.3390/antibiotics10010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
42 Smith SM, O'Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 2019;35:6-13. [PMID: 30489412 DOI: 10.1097/MOG.0000000000000497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
43 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
44 Gisbert JP, Molina-Infante J. Current treatment of Helicobacter pylori infection. Med Clin (Barc) 2017;148:20-2. [PMID: 27916266 DOI: 10.1016/j.medcli.2016.10.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Botija G, García Rodríguez C, Recio Linares A, Campelo Gutiérrez C, Pérez-Fernández E, Barrio Merino A. Antibiotic resistances and eradication rates in Helicobacter pylori infection. An Pediatr (Engl Ed) 2021;95:431-7. [PMID: 34810153 DOI: 10.1016/j.anpede.2020.10.010] [Reference Citation Analysis]
46 Salillas S, Alías M, Michel V, Mahía A, Lucía A, Rodrigues L, Bueno J, Galano-frutos JJ, De Reuse H, Velázquez-campoy A, Carrodeguas JA, Sostres C, Castillo J, Aínsa JA, Díaz-de-villegas MD, Lanas Á, Touati E, Sancho J. Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori -Infected Mice. J Med Chem 2019;62:6102-15. [DOI: 10.1021/acs.jmedchem.9b00355] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
47 Mcnicholl AG, O’morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp‐Eureg on Behalf of the National Coordinators. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg). Helicobacter 2019;24. [DOI: 10.1111/hel.12630] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
48 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
49 McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, Zakharova NV, Sarsenbaeva AS, Bujanda L, Perez-Aisa Á, Vologzhanina L, Zaytsev O, Ilchishina T, Coba C, Lasala JP, Alekseenko S, Modolell I, Molina-Infante J, Ruiz-Zorrilla Lopez R, Alonso-Galan H, Moreno NF, Hinojosa J, Santaella I, Varela P, Gonzalez-Cordero PL, Barrio J, Dominguez-Jimenez JL, Nuñez O, Alcedo J, Nyssen OP, Caldas M, Donday MG, Shvetz O, Megraud F, O'Morain C, Gisbert JP. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020;18:89-98. [PMID: 30978536 DOI: 10.1016/j.cgh.2019.03.048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
50 Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
51 Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T, Bordin D, Smith S, Lamy V, Caldas M, Resina E, Muñoz R, Cosme Á, Puig I, Megraud F, O'Morain C, Gisbert JP; The Hp-EuReg Investigators. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel) 2021;10:1058. [PMID: 34572640 DOI: 10.3390/antibiotics10091058] [Reference Citation Analysis]
52 Jaka H, Rhee JA, Östlundh L, Smart L, Peck R, Mueller A, Kasang C, Mshana SE. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC Infect Dis 2018;18:193. [PMID: 29699490 DOI: 10.1186/s12879-018-3099-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
53 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel) 2021;10:1028. [PMID: 34572610 DOI: 10.3390/antibiotics10091028] [Reference Citation Analysis]
55 García García de Paredes A, Teruel Sánchez-vegazo C, Hernanz Ruiz N, Ferre Aracil C, Rodríguez de Santiago E, Aguilera Castro L, Sierra Morales M, Albillos A. Do patients with iron deficiency without anemia benefit from an endoscopic examination?: Endoscopic evaluation of iron deficiency. Journal of Digestive Diseases 2017;18:416-24. [DOI: 10.1111/1751-2980.12495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
56 Macías-García F, Bastón-Rey I, de la Iglesia-García D, Calviño-Suárez C, Nieto-García L, Domínguez-Muñoz JE. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Helicobacter 2019;24:e12546. [PMID: 30346636 DOI: 10.1111/hel.12546] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
57 Cosme A, Torrente Iranzo S, Montes Ros M, Fernández-reyes Silvestre M, Alonso Galán H, Lizasoain J, Bujanda L. Helicobacterpylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies: XXXX. Helicobacter 2019;24:e12557. [DOI: 10.1111/hel.12557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]